Bovay Lecture features Barzilai March 21
Nir Barzilai, MD, director of the Institute for Aging Research at the Albert Einstein College of Medicine, will present the 2025 Harry E. Bovay, Jr. Annual Lecture, at 11 a.m. March 21 in the Beth Robertson Auditorium at the Institute of Molecular Medicine.
Barzilai will present on “How to die young at a very old age.”
Barzilai is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine his a professor in the departments of Medicine and Genetics and the director of the Einstein-National Institutes of Health Nathan Shock Center of Excellence in the Basic Biology of Aging.
He made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging.
Barzilai is a co-founder and the president of the Academy for Health and Lifespan Research. He is also on the American Federation for Aging Research board of directors, where he co-leads its biomarker effort, TAME, and Super Agers initiative. He is an executive of the Longevity Biotech Association and serves on the council of the Healthy Longevity Medicine Society.
The Harry E. Bovay, Jr. Lecture honors the life and work of Harry E. Bovay, Jr., distinguished visionary, entrepreneur, civic leader, and philanthropist, who made a significant contribution to The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases. His contribution helped bridge the gap between the laboratory bench and the patient bedside, between identifying the molecular causes of diseases and actually preventing them.